Avigen Commences Clinical Trials for AV650 in Neuromuscular Spasticity

Avigen, Inc. announces the commencement of Phase I clinical trials for AV650, a new chemical entity (NCE) for the treatment of neuromuscular spasticity and spasm. The trials will assess safety, pharmacokinetic profile, and lack of sedation in normal volun...